{"id":1893,"date":"2023-08-30T11:08:56","date_gmt":"2023-08-30T09:08:56","guid":{"rendered":"http:\/\/localhost:8888\/progetti\/laramed\/?page_id=1893"},"modified":"2026-10-05T11:02:35","modified_gmt":"2026-10-05T09:02:35","slug":"laramed","status":"publish","type":"page","link":"https:\/\/web.infn.it\/LARAMED\/","title":{"rendered":"Laramed"},"content":{"rendered":"
\n
\"\"<\/figure>\n<\/div>\n\n\n

<\/p>\n\n\n\n

NEWS!<\/strong><\/p>\n\n\n\n

An important milestone has been achieved in September 2026: the radionuclide copper-67 (\u2076\u2077Cu<\/strong><\/em>) has been produced for the first time in Italy in the framework of the CUPRUM_TTD<\/a> project, funded by INFN\u2019s National Scientific Commission 5 (CSN5) and developed at the Legnaro National Laboratories<\/em>. 

This result marks a significant milestone in a multi-year research and development effort, carried out through close collaboration among INFN, the University of Ferrara, and the IRCCS Sacro Cuore Don Calabria Hospital. Such important achievement is the result of years of experimental work, multidisciplinary expertise, and continuous collaboration among the nuclear physicists, engineers, chemists, and researchers involved in the project.<\/em><\/p>\n\n\n\n

\u2076\u2077Cu is one of the therapeutic radionuclides of greatest international interest due to its unique physical and radiobiological characteristics. Its emission of beta-minus particles allows it to be used in the treatment of various types of cancer, while the concomitant emission of \u03b3 photons enables SPECT imaging, which is useful for assessing biodistribution, monitoring therapy, and dosimetry. Its use therefore appears particularly promising in the field of personalized nuclear medicine, especially for the treatment of cancers such as prostate cancer and glioblastoma.
<\/em>
The production and purification of \u2076\u2077Cu<\/strong> following the irradiation of an enriched \u2077\u2070Zn<\/strong> target represent a significant step toward making this radionuclide available for future preclinical and clinical research, confirming the role of LNL-INFN in the development of advanced technologies and infrastructure to support nuclear medicine and biomedical applications. Additional information can be found here<\/a>. <\/em><\/p>\n\n\n

\n
\"\"
The enriched \u2077\u2070Zn target coin realized with the Spark Plasma Sintering<\/a> method.<\/figcaption><\/figure>\n<\/div>\n\n\n

<\/p>\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

The LARAMED team at the 12th International Conference on Isotopes (12ICI: www.12ici.org<\/a>), held in Florence in February 2026.<\/p>\n\n\n\n

<\/p>\n\n\n\n

\u201cNuclear for Health<\/em>\u201d: A dialog among science, business and istitutions for the health of future.<\/h2>\n\n\n\n

Liliana Mou, a technologist of the Legnaro National Laboratories and member of the LARAMED team, restate the preeminence international role of INFN in the research on medical radionuclides:<\/p>\n\n\n\n

\n
Convegno \u201cNucleare per la salute\u201d: il dialogo tra scienza, impresa e istituzioni per la sanit\u00e0 del domani<\/a><\/blockquote>